We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue

The OncoMasTR Test Accurately Identifies Risk of Breast Cancer Recurrence

By LabMedica International staff writers
Posted on 29 Jun 2021
Print article
Image: OncoMasTR is a six-gene signature test that can predict the likelihood of breast cancer spreading to a distant site in the body and reappearing (Photo courtesy of University College Dublin)
Image: OncoMasTR is a six-gene signature test that can predict the likelihood of breast cancer spreading to a distant site in the body and reappearing (Photo courtesy of University College Dublin)
A recent paper confirmed that the Oncomark (Dublin, Ireland) OncoMasTR test can accurately identify the risk for disease recurrence in patients with hormone receptor–positive HER2-negative early-stage breast cancer.

OncoMasTR is a multi-parameter prognostic test for ER-positive, HER2-negative early stage breast cancer patients with up to three involved lymph nodes. The OncoMasTR RT-qPCR test measures the expression of three prognostic genes (plus three reference genes) and estimates the probability of distant recurrence for breast cancer patients, thereby aiding clinicians in determining the best treatment options for their patients and avoiding the costs and severe side-effects from unwarranted chemotherapy, ultimately improving the quality of life of the patient.

Investigators at University College Dublin (Ireland) compared the efficacy of the OncoMasTR test to seven other commercially available assays. Among these was the Exact Sciences (Madison, WI, USA) Oncotype DX Breast Recurrence Score Test, which analyzes the activity of 21 genes that can influence how likely a cancer is to grow and respond to treatment.

For this study, the investigators analyzed tissue samples from 404 Irish women who were enrolled in the Trial Assigning Individualized Options for Treatment [Rx]. Gene expression measured via RT-qPCR was used to calculate the OncoMasTR Molecular Score (OMm) and a composite risk score, the OncoMasTR Risk Score (OM).

Results revealed that OMm and OM were more prognostic for distant recurrence-free survival and provided significant additional prognostic information to all other assessment tools/factors assessed. In addition, the OM correctly classified more patients with distant recurrences into the high-risk category than other risk classification tools. Similar results were observed for invasive disease-free survival.

Senior author Dr. William Gallagher, professor of cancer biology at University College Dublin, said, "This key clinical validation study showed that the OncoMasTR test has truly excellent performance in terms of predicting outcome of these patients, with improved performance versus the currently used approaches in the clinic. This may help clinicians to optimize treatment decisions."

The OncoMasTR paper was published in the June 2, 2021, online edition of European Journal of Cancer.

Related Links:
University College Dublin
Exact Sciences

Gold Supplier
CoviPath COVID-19 RT-PCR Kit
Automated Pipetting Solution
COVID-19 IgM/IgG Antibody Test
MosaiQ COVID-19 Antibody Microarray
SARS-CoV-2 Detection Kit
Loopamp SARS-CoV-2 Detection Kit

Print article



view channel

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.